Drug Profile
TAK 915
Alternative Names: TAK915Latest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Takeda
- Class
- Mechanism of Action Type 2 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Schizophrenia
Most Recent Events
- 01 Aug 2016 Takeda completes a phase-I trial in Schizophrenia (In volunteers) in USA (NCT02461160)
- 30 Apr 2016 Takeda completes a phase I trial in Healthy volunteers in USA (NCT02584569)
- 27 Oct 2015 Takeda plans a phase I trial in Healthy volunteers in USA (NCT02584569)